A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

The rapid evolution in personalized healthcare has driven the development of wearable biomedical devices, with microneedle ...

Vancouver, British Columbia--(Newsfile Corp. - November 12, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or ...

In a new study, researchers discovered a potential new gene biomarker, ELF1, a protein coding gene, that can be used to ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

Researchers found that a chromosome 6 locus within the HLA region was significantly associated with severe vs less severe ulcerative colitis.

Rheumatoid arthritis (RA) is the most common form of chronic inflammatory arthritis, characterized by synovitis and ...

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

Patient-derived organoids (PDOs) are revolutionizing cancer research, enhancing drug testing and personalized treatment ...

MYND Life Sciences plans to issue 4 million shares to eliminate $3.5 million in debt, including restructuring an outstanding debenture, to enhance shareholder value and focus on developing their ...